Wave Life Sciences Ltd.

WVE

SG9999014716

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
6.26 ^USD	+6.10%		+11.39%	+23.96%

15/05	Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target	MT
09/05	Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024

Wave Life Sciences Ltd. Elects Aik Na Tan to the Board

August 19, 2020 at 02:54 am IST

Wave Life Sciences Ltd. elected Aik Na Tan to the board at the AGM held on August 12, 2020.

Latest news about Wave Life Sciences Ltd.

Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target	15/05	MT
Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024	09/05
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Posts Q1 Revenue $12.5M, vs. Street Est of $23M	09/05	MT
Wave Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer	09/05	CI
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency	30/04	CI
Wave Life Sciences Ltd. Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing	23/04	CI
Mizuho Adjusts Price Target on WAVE Life Sciences to $19 From $10, Maintains Buy Rating	12/03	MT
H.C. Wainwright Adjusts Price Target on WAVE Life Sciences to $15 From $8, Maintains Buy Rating	07/03	MT
Sector Update: Health Care Stocks Higher Late Afternoon	07/03	MT
WAVE Life Sciences Shares Surge After Q4 Beats Estimates	07/03	MT
Transcript : Wave Life Sciences Ltd., Q4 2023 Earnings Call, Mar 06, 2024	06/03
Wave Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Wave Life Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03	CI
Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q4 Revenue $29.1M, vs. Street Est of $19.8M	06/03	MT
Transcript : Wave Life Sciences Ltd. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM	11/01
Leerink Partners Upgrades WAVE Life Sciences to Outperform From Market Perform, Price Target at $12	19/12	MT
Wave Life Sciences Starts Dosing in Neuromuscular Disorder Study	15/12	MT
Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy	15/12	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07/12	MT
Sector Update: Health Care	07/12	MT
Investor Sentiment Muted Ahead of November Jobs Report, Driving Quiet Premarket Action for US Equity Futures	07/12	MT
Top Premarket Decliners	07/12	MT
WAVE Life Sciences Kicks off $100 Million Offering; Shares Plunge in Premarket Activity	07/12	MT
Wave Life Sciences Ltd. Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency	07/12	CI

Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntingtonâs disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Wave Life Sciences Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.26 USD

Average target price

12.86 USD

Spread / Average Target

+105.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WAVE LIFE SCIENCES LTD.	+23.96%	767M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs